Home » Business News » 2011 » February » February 16, 2011

New analysis with Alpharadin to be presented at 2011 Genitourinary Cancers Symposium

February 16, 2011 - London


Oslo, Norway, 16 February 2011 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, notes that a new analysis of clinical data from its phase II clinical program with Alpharadin will be presented at the 2011 Genitourinary Cancers Symposium* in Orlando, FL, USA (17-19 February 2011).


The analysis concluded that the effect of Alpharadin (radium-223) on normalizing serum markers of bone metabolism, including alkaline phosphatase (ALP), in patients with bone metastases from castration-resistant Prostate cancer is associated with significantly better overall survival.


Poster title: Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant Prostate cancer (CRPC) treated with radium-223.


Presented by Dr. Christopher Parker (Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK)
Abstract #49
Thursday 17 February, 11:45-13:00 (ET)
General Poster Session A: Prostate cancer
Orlando World Center Marriott


*The 2010 Genitourinary Cancers Symposium is being co-sponsored by three leading medical specialty societies, including the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).





For further information, please contact


Andrew Kay, CEO
Øystein Soug, CFO

+47 2300 7990 / +47 4840 1360 (mob)
+47 2300 7990 / +47 9065 6525 (mob)

International media enquiries:
Mark Swallow/David Dible
Citigate Dewe Rogerson

+44 207 638 9571
US investor enquiries:
Jessica Lloyd
The Trout Group

+1 646 378 2928


About Algeta


Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.


Algeta's lead product Alpharadin (based on radium-223) is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced cancer. Its localized action helps preserve the surrounding healthy tissue thereby limiting side-effects.


The development of bone metastases represents a serious development for cancer patients as they are associated with a dramatic decline in patient health and quality of life, ultimately leading to death. Bone metastases represent a major unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g. prostate, breast and lung.


Alpharadin is being developed under a development and commercialization agreement with Bayer Schering Pharma AG, a major pharmaceutical company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from castration-resistant prostate cancer (CRPC). Alpharadin is also under investigation in phase II clinical trials as a potential new treatment for bone metastases in endocrine-refractory breast cancer patients, and in a phase I/IIa trial in combination with docetaxel chemotherapy in for bone metastases CRPC patients.


Algeta also aims to develop a future pipeline of tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227, through selective in-licensing and/or acquiring innovative technologies and tumor-targeting molecules.


The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).


Alpharadin and Algeta are trademarks of Algeta ASA.


Forward-looking Statement
This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE


Comment on this story